Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.

NCT02055066 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT02055066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02055066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.
Lead sponsor
argenx
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2014
Completion date
March 31, 2017
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer